<DOC>
	<DOC>NCT02245360</DOC>
	<brief_summary>To investigate the immunologic effects and safety of 60-day treatment of the Standardized Quality units (SQ) grass Sublingual immunotherapy (SLIT)-tablet in adult subjects with grass pollen-induced allergic rhinoconjunctivitis in a double-blind, placebo-controlled study.</brief_summary>
	<brief_title>Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<criteria>clinical history consistent with grass polleninduced allergic rhinoconjunctivitis. Use of symptomatic treatment of grass polleninduced allergic rhinoconjunctivitis. Positive skin prick test response (wheal diameter ≥3 mm) to Phleum pratense. If asthma, daily use of Inhaled corticosteroid (ICS) should be ≤400 microgram budesonide or equivalent Moderate or higher level of Phleum pratense specific IgE (Immunoglobulin E) (defined as ≥IgE Class 2; or ≥0.70 Kilo Units/liter (kU/L)) Reduced lung function (defined as FEV1 &lt; 70% (FEV1=Forced Expiratory Volume in 1 second) of predicted value after adequate pharmacologic treatment) measured at Visit 1 and Visit 2 Clinical history of uncontrolled asthma within 3 months prior to the screening visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>GRAZAX</keyword>
</DOC>